Eiger BioPharmaceuticals 2017-06-30T18:30:18+00:00

IN THE NEWS
1408, 2017

Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results

Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results - Five Phase 2 Programs Advancing in Multiple Orphan Indications - Multiple Clinical and Regulatory Milestones Expected 2017-2018 PALO ALTO, Calif., August 14, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three months and six months ended June 30, 2017 and provided a business update. “We continue to advance our pipeline of novel treatments for [...]

808, 2017

Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16th

Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16th PALO ALTO, Calif. – August 8, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at the 2017 Wedbush PacGrow Healthcare Conference at 12:45 pm ET on Wednesday, August 16, 2017, at  Le Parker Meridien in New York City. A [...]

2707, 2017

Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection PALO ALTO, Calif., July 27, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for pegylated interferon lambda 1a (Lambda) as a potential treatment for chronic hepatitis delta virus (HDV) infection. "We are very pleased that the FDA has granted [...]